Astrana Health, Inc. (ASTH) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - Astrana Health, Inc. reported a quarterly loss of $0.15 per share, missing the Zacks Consensus Estimate of$ 0.09, and a decline from earnings of $0.26 per share a year ago, representing an earnings surprise of -266.67% [1] - The company posted revenues of$ 665.21 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 5.42%, and showing significant growth from year-ago revenues of $353.04 million [2] - Over the last four quarters, Astrana Health has surpassed consensus revenue estimates three times, but has only exceeded EPS estimates once [2] Stock Outlook - Astrana Health shares have increased approximately 11.3% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is$ 0.34 on revenues of $574.8 million, and for the current fiscal year, it is$ 1.41 on revenues of $2.56 billion [7] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which Astrana Health belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5] Estimate Revisions - The estimate revisions trend for Astrana Health is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6]